One-pill, once-daily combination superior to sofosbuvir plus ribavirin, with no cases of virologic failure in open-label phase III trial.
Use of shorter 12-week treatment regimen highly effective in patients with F3 disease.
Similar SVR24 rates in white patients vs black patients; SVR12 rate not affected by baseline RAVs in patients with genotype 1a HCV infection.
Low rates of discontinuation due to AEs, treatment-related serious AEs, and/or grade 3 and 4 lab abnormalities in this interim analysis.
Analysis finds 8-week regimen is underused, despite being highly effective in qualifying patients.
High SVR rates maintained across patient subgroups, including cirrhotic and treatment-experienced patients; adverse event rates similar to placebo.
Both 12-week and 16-week regimens of daclatasvir plus sofosbuvir plus ribavirin were well tolerated, even in cirrhotic, treatment-experienced patients usually considered difficult to treat.
No relapse in noncirrhotic patients regardless of inclusion of ribavirin; no relapse in cirrhotic patients with 16 weeks of treatment including ribavirin.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.